CMND and CWY0 Related Headlines
Go Back- Clearmind Medicine receives Johns Hopkins approval for CMND-100 trial parts
- Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
- Clearmind Medicine announces 1-for-10 reverse stock split effective May 21
- Clearmind Medicine Announces 1-for-10 Reverse Share Split
- Clearmind Medicine signs research deal to study MEAI with tirzepatide
- Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
- Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
- Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
- Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
- Clearmind Medicine evaluates psychedelic drug for FDA breakthrough status
- Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
- Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
- Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
- Clearmind Medicine files Hong Kong patent for depression therapy combo
- Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
- Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
- Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
- Clearmind Medicine reports positive safety data from CMND-100 trial
- Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
- Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment
- Clearmind Medicine regains compliance with NASDAQ stockholders' equity rule
- Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
- Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
- Clearmind Medicine receives approval to continue phase I trial
- Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review
- Clearmind Medicine gets approval to expand alcohol disorder trial in Israel
- Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
- Clearmind Medicine receives NASDAQ notice for equity deficiency
- Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
- Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
- Clearmind Medicine files patent for obesity and liver disease therapy
- Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
CMND and CWY0 Related Press Releases
Go Back- Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
- Clearmind Medicine Announces 1-for-10 Reverse Share Split
- Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
- Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
- Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
- Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
- Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
- Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
- Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
- Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
- Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
- Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
- Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
- Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment
- Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
- Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
- Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review
- Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
- Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
- Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
- Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
